Although levodopa remains the most physiological and probably the best available pharmacological treatment These assessments were: (a) unilateral hand tapping count over 30 seconds; (b) time taken to rise from a standard armless chair, walk 6 m, and return to the chair (inability to complete the task within 30 seconds was assigned a time of 30 seconds for the analysis of results); and (c) measurement of regional tremor and dyskinesia according to simple five-point scales (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = violent/incapacitating) for head, trunk, and each limb (maximum score 24).
Before the levodopa dose ("off" phase) and at the time of peak motor improvement as judged by the serial hand tapping and walking time measurements ("on" phase), patients were scored on a modified Webster disability scale (scoring for 12 areas of motor function giving a maximum disability score of 36).'
These data were not available in one patient for the initial study.
The amplitude of motor response for each of the motor assessments was the absolute value obtained by subtracting the "on" from "off' results. The duration of response was defined as the time from the onset of response to the return to the baseline motor state. To analyse the changes in motor function with respect to the severity of disease, patients were divided into three subgroups according to disease duration (less than six years, six to 10 years, and greater than 10 years) and also to the modified Webster scale "off' phase disability in the initial study (scores of 9-16, 17-24, and 25-32) as a measure of the severity of motor deficit without pharmacological treatment.
Although no major changes in pharmacological treatment occurred over the study interval, there were some adjustments of both levodopa dose and other anti-parkinsonian medication. The effects of the patients' usual drugs were minimised by the standardised testing conditions described here, but treatment was not otherwise changed before the second assessment on the basis that an alteration of regular drug treatment may have destabilised motor function and introduced additional experimental error.
STATISTICAL ANALYSIS
Student's t test was used to assess statistical significance. Paired data were analysed in comparing the initial and final study results.
Results
An unequivocal motor response at the initial assessment of levodopa dose occurred in each patient, accompanied by drug-induced dyskinesia in all but one patient. On the second occasion, 22 patients had a definite response and the remaining patient, although not responding to the standard levodopa 250 mg/ carbidopa 25 mg dose, responded to a double dose. This patient's data were included in the assessment of the magnitude and pattern of motor response but were excluded from the analysis of duration and latency.
PROGRESSION OF DISABILITY AND MAGNITUDE OF RESPONSE TO LEVODOPA
The total "off' phase Webster disability score increased over the follow-up period in all but four patients. The mean (range) "off" score was initially 20 (9-32) and subsequently 25 (17-33) (p < 0-001). The increase in "off' score was greatest in those patients with a disease duration of less than six years when initially studied (mean increase 8-0) and similar in those with a disease duration of six to 10 years (3 8) and more than 10 years (4 2). Figure 1 shows these results.
The "on" phase Webster score deteriorated in each patient. The mean (range) initial "on" score was 6-2 (1-13) and the mean (range) final "on" score was 11 (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . This deterioration was similar in the three groups classified by duration of disease.
The mean amplitude of levodopa motor response was therefore unchanged over the three year follow-up period. The mean response amplitude increased by 2-0 points in the less than six years' disease duration group but decreased by 0 7 in the six to 10 group, and decreased slightly by 0-2 more than 10 years' group (differenc significant). Analysis according to initia phase modified Webster score showe the least disabled patients had a mean tude increase of 3-6 over the three whereas the amplitude in patients with erate and severe "off" phase dis decreased by 1-6 (p < 0-02 for diff between greatest and least "off" phase c ity groups).
The "off" phase walking time increa three seconds (p < 0.02) and the "on" time increased by four seconds (p < but the response amplitude was 12 anc the initial and final studies respective significant difference). Hand tapping showed a similar trend with a mild det tion of the "off' and "on" phase results were not significant. The response amj decreased slightly (23 initial, 21 final).
TOPOGRAPHIC ASPECTS OF MOTOR DISAB AND RESPONSE TO LEVODOPA
In the initial study, modified Webstei scores for arm swing, gait, rigidity, p( and self-care contributed most to motor improvement after levodopa doses, whereas seborrhoea, balance, and speech were the least responsive. There was little change in the response pattern over three years, with features reflecting multiple facets of parkinsonian disability such as gait, arm swing, and ability to rise from a chair still contributing to the bulk of improvement, whereas balance, speech, and seborrhoea contributed the least -(see table 2 ). Modified Webster scale scores representing "midline" motor functions including locomotion (gait, facial movement, speech, balance, rising from chair) were compared with lateralised upper limb motor scores (bradykinesia, 20 rigidity, arm swing, tremor). The amplitude of motor response was conserved for the two wer bars) sets of scores (mean response amplitude of lisease at "midline" scores 1-I in the initial and final studies, mean "upper limb" score amplitude 1-4 initial and 1-5 final). years' in the DURATION AND LATENCY OF MOTOR RESPONSE ,es not There was a 17% reduction in the mean 1 "off' (range) duration of motor response from 199 d that (100-345) minutes initially to 168 (43-324) ampli-minutes (p < 0 05). This reduction was greatyears est in patients with a disease duration of six to mod-10 years (mean reduction 61 minutes) and sability least for those with Parkinson's disease for 'erence more than 10 years (mean reduction 16 minlisabil-utes). Shortening of the response duration over three years varied widely from a reducsed by tion to 30% of the initial response duration to phase no change or increased duration in the final 0-0 1), study in seven patients. Evolution from stable I 11 in motor function to clinically significant motor ly (no oscillation occurred in only one patient who counts had a response duration of 255 minutes in the -eriora-two studies. Figure 2 shows the response which duration results graphically, grouped accordplitude ing to disease duration and initial "off" phase Webster scale disability.
There was no significant change in the IILITY latency to onset of the motor response (mean latency to onset initially 39 minutes and at r scale review 37 minutes). all but three maintained this respc follow up. The mean tremor score "off' phases had worsened from 3-4 (p < 0 01).
Discussion
This unique longitudinal study of response characteristics in a cohort of with parkinsonian motor fluctuations c several aspects of the deterioration ir ment efficacy due to disease progi Despite significant increases in motor di scores and dyskinetic involuntary move the capacity to respond to levodopa c deteriorate significantly, with a roughli rate of decrease in "on" and "off' sco conservation of response amplitude. quantitative disability scale scoring a less observer-dependent hand tappir walking measurements showed this tr "off' phase motor function can be rega a measure of endogenous striatal dol deficiency, the progressive reduction i scores reflects progressive nigral cell loE motor improvement which occurs "on" phases depends on the presence of a suf-A ficient number and sensitivity of striatal dopamine receptors plus the integrity of essential non-dopaminergic components of the motor system. Disease progression thus brings increasing reliance on pharmacological striatal dopamine receptor stimulation. This may explain why the best motor state attainable with levodopa treatment decreases and the associated dyskinetic involuntary movements increase. We found no evidence that certain motor deficits such as impairment of speech, gait, and upright postural stability become progressively unresponsive to levodopa as the disease progresses in individual patients, based on the analysis of modified Webster scale scoring and the timed walking task. These aspects of motor function seem to be generally less responsive to levodopa and in some patients who are older at the time of onset of the disease speech and gait are more affected, associated with a modest overall B response to levodopa.6 In individual patients, however, these deficits seem to retain roughly the same magnitude of response despite worsening "on" and "off" motor function.
The mean age of disease onset in this study group is younger and the mean treatment duration longer than is usual for an unselected parkinsonian population. This reflects our sampling of patients with motor fluctuations, a complication of treatment more common in patients with early onset disease.7 The fact, however, that more than 50% of patients develop motor fluctuations after five years of levodopa treatment8 makes these results generally relevant to the management of Parkinson's disease. Our results show significant changes in motor scores over three years which can reasonably be attributed to disease tndfinal progression. The term "disease progression" lying as used in this discussion encompasses the clinical manifestation of a variety of pathological changes affecting the motor system, )nse at including neuronal loss associated with Lewy during bodies in and beyond the substantia nigra as to 4-5 well as the effects of coexistent vascular or Alzheimer-type disease.9 Different combinations and rates of progression of these changes may explain some of the variability in the evolution of the pattern of response to levodopa.
motor Our three year follow-up period does not )atients exclude the possibility that some patients with clarifies motor fluctuations will eventually show a loss i treat-of response amplitude over time, possibly those ression. with more widespread degenerative disease. isability
The mean duration of the motor response -ments, to levodopa decreased with disease progresdid not sion although this did not occur evenly, with y equal the greatest shortening occurring in patients res and with relatively short disease duration and little Semi-change in patients with longstanding disease. nd the More recently diagnosed patients with more ig and stable motor responses to levodopa had a end. If longer mean motor response duration than rded as those with longstanding disease, many of pamine whom had severe motor fluctuations. The difn "off' ference in the duration of motor response was ss. The not great, however, and there was considerduring able overlap between the groups. shows that "off" phase disability (taken to reflect the degree of endogenous dopamine deficiency) correlates poorly with response duration. Nutt et al 1 found that the mean motor response to intravenous levodopa infusion was shorter in patients with a fluctuating response than in those with a stable response and untreated patients, but that, again, considerable overlap was present and the difference did not attain statistical significance. All patients in our study with severe motor fluctuations had large response amplitudes. Although we showed that the mean duration of response to levodopa decreases with disease progression, severe fluctuations were seen in patients with relatively long responses to the test dose, and in one patient motor fluctuations developed over the three year period without any change in the measured duration of response. These observations emphasise the importance of a widening response amplitude and increasing "off" phase disability in the genesis of motor fluctuations. In many patients the motor response amplitude must increase as a stable motor response early in the course of levodopa treatment gives way to motor fluctuations. This longitudinal study suggests that the amplitude of response is stable with further disease progression and that patients who have a larger response amplitude and develop motor fluctuations may not lose their capacity to benefit from levodopa. This agrees with the clinical experience that when patients with motor fluctuations enter the advanced stages of Parkinson's disease, fluctuation continues with distinct "on" and "off" phases but overall motor function decreases as "off" phase disability becomes extreme, and "on" phases are increasingly marred by involuntary movements and neuropsychiatric toxicity. A patient with motor fluctuations has a response to treatment which is unsatisfactory compared with his or her own responses soon after starting treatment with levodopa or with patients with milder disease. This group of patients appears to maintain a substantial amplitude of response to levodopa over time, however, and may continue to benefit from the manipulation of dopaminergic treatment.
